TNFSF10 and ovarian carcinoma: A recent study demonstrated increased activity of recombinant TRAIL in patient-derived ovarian carcinoma cells when combined with bortezomib, while primary hepatocytes remained resistant, indicating low toxicity of the combination treatment in normal cells.40 The combined cytotoxic effect of bortezomib and TRAIL in both HPV+ and HPV− cell lines suggests a promising novel therapeutic approach for the effective and selective killing of HNSCCs.